Citigroup Inc Atea Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 57,833 shares of AVIR stock, worth $194,897. This represents 0.0% of its overall portfolio holdings.

Number of Shares

57,833

Previous 19,197 201.26%

Holding current value

$194,897

Previous $63,000 206.35%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$3.17 - $4.02 $122,476 - $155,316	38,636 Added 201.26%	57,833 $193,000
Q2 2024 Aug 12, 2024	BUY	$3.31 - $4.04 $14,630 - $17,856	4,420 Added 29.91%	19,197 $63,000
Q1 2024 May 10, 2024	BUY	$3.09 - $4.56 $7,057 - $10,415	2,284 Added 18.28%	14,777 $59,000
Q4 2023 Feb 09, 2024	BUY	$2.8 - $3.35 $31,970 - $38,250	11,418 Added 1062.14%	12,493 $38,000
Q3 2023 Nov 09, 2023	SELL	$3.0 - $3.79 $122,187 - $154,362	-40,729 Reduced 97.43%	1,075 $3,000
Q2 2023 Aug 10, 2023	BUY	$3.21 - $5.06 $125,103 - $197,203	38,973 Added 1376.65%	41,804 $156,000
Q1 2023 May 11, 2023	SELL	$3.0 - $4.97 $16,071 - $26,624	-5,357 Reduced 65.43%	2,831 $9,000
Q4 2022 Feb 09, 2023	SELL	$4.35 - $6.17 $48,802 - $69,221	-11,219 Reduced 57.81%	8,188 $39,000
Q3 2022 Nov 10, 2022	BUY	$5.49 - $8.79 $1,350 - $2,162	246 Added 1.28%	19,407 $110,000
Q2 2022 Aug 10, 2022	SELL	$5.33 - $8.18 $13,463 - $20,662	-2,526 Reduced 11.65%	19,161 $136,000
Q1 2022 May 12, 2022	SELL	$5.5 - $9.19 $106,040 - $177,183	-19,280 Reduced 47.06%	21,687 $157,000
Q4 2021 Feb 10, 2022	BUY	$7.67 - $44.59 $255,549 - $1.49 Million	33,318 Added 435.59%	40,967 $366,000
Q3 2021 Nov 10, 2021	BUY	$21.33 - $35.06 $163,153 - $268,173	7,649 New	7,649 $268,000

Others Institutions Holding AVIR

# of Institutions

112

Shares Held

52.4M

Call Options Held

900

Put Options Held

126K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $281M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account